High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center.
Resistance to the novel β-lactam/β-lactamase inhibitor combination ceftazidime-avibactam (CAZ-AVI) among carbapenem-resistant Enterobacteriaceae (CRE) has infrequently been reported in the United States. We report unexpectedly high rates of resistance to CAZ-AVI in CRE bloodstream isolates at our institution associated with the nonoutbreak spread of New Delhi metallo-β-lactamase in diverse Enterobacteriaceae species.
Division of Pharmacy.|Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Texas.
Samuel L
SL
Aitken
Department of Laboratory Medicine.
Jeffrey J
JJ
Tarrand
JMI Laboratories, North Liberty, Iowa.
Lalitagauri M
LM
Deshpande
Division of Pharmacy.
Frank P
FP
Tverdek
Division of Pharmacy.
Anne L
AL
Jones
Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center.
Samuel A
SA
Shelburne
Division of Pharmacy.|Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center.|Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Texas.
Randall A
RA
Prince
Department of Laboratory Medicine.
Micah M
MM
Bhatti
Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center.
Kenneth V I
KVI
Rolston
JMI Laboratories, North Liberty, Iowa.
Ronald N
RN
Jones
JMI Laboratories, North Liberty, Iowa.
Mariana
M
Castanheira
Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center.
Roy F
RF
Chemaly
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D053961:Azabicyclo Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D002173:Cancer Care Facilities; D002442:Ceftazidime / Q000494:pharmacology / Q000627:therapeutic use*; D002675:Child, Preschool; D004338:Drug Combinations; D024881:Drug Resistance, Bacterial; D004755:Enterobacteriaceae / Q000187:drug effects / Q000201:enzymology / Q000235:genetics; D004756:Enterobacteriaceae Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D055815:Young Adult; D001618:beta-Lactamases
D000900:Anti-Bacterial Agents; D053961:Azabicyclo Compounds; D004338:Drug Combinations; C000595613:avibactam, ceftazidime drug combination; D002442:Ceftazidime; D001618:beta-Lactamases; C552864:beta-lactamase NDM-1
CRE; NDM; bacteremia; carbapenemase; ceftazidime-avibactam